ライフサイエンスコーパス: osteocalcin

1 ased levels of insulin and undercarboxylated osteocalcin.

2 cular proteins in addition to collagen I and osteocalcin.

3 epatic tissues such as matrix Gla protein or osteocalcin.

4 proteoglycans, and matrix proteins, such as osteocalcin.

5 21days, and quantified by real time QPCR for osteocalcin.

6 amidation of a natural peptide derived from osteocalcin.

7 ers of osteogenesis alkaline phosphatase and osteocalcin.

8 ed serum levels of the bone formation marker osteocalcin.

9 activity of the insulin-sensitizing hormone osteocalcin.

10 promising bone resorption and bioactivity of osteocalcin.

11 and in humans by increasing the activity of osteocalcin.

12 ectly influenced by the bone-derived hormone osteocalcin.

13 re improved by infusion of undercarboxylated osteocalcin.

14 ine the carboxylation status and function of osteocalcin.

15 ting glucose metabolism through secretion of osteocalcin.

16 esponsible for decreasing the bioactivity of osteocalcin.

17 t marker genes such as bone sialoprotein and osteocalcin.

18 tomorphometry and real-time RT-PCR for human osteocalcin.

19 RUNX2, osterix, and the osteoblast protein, osteocalcin.

20 : type I collagen, alkaline phosphatase, and osteocalcin.

21 d expression of Runx2 (3.5-fold, P<0.05) and osteocalcin (4-fold, P<0.05).

22 Here we show that osteocalcin, a bone-derived hormone, regulates beta-cell

23 Among these youthful factors, we identify osteocalcin, a bone-derived molecule, as a direct hormon

24 rgy balance by stimulating the production of osteocalcin, a bone-derived protein that promotes insuli

25 netically forced expression of Runx2/p57 and osteocalcin, a classical bone-related target gene, under

26 rming osteoblasts and enhances production of osteocalcin, a secreted mediator of insulin sensitivity,

27 tween osteoblast-specific insulin signaling, osteocalcin activation and gluco-metabolic homeostasis h

28 ody glucose homeostasis because it increases osteocalcin activity.

29 els of both insulin-like growth factor 1 and osteocalcin also were determined.

30 round microcracks and a higher expression of osteocalcin -an osteogenic protein known to be promoted

31 timulates bone cells to produce and activate osteocalcin, an endocrine hormone that increases the eff

32 from its ability to suppress the activity of osteocalcin, an osteoblast-derived hormone favoring gluc

33 a product that decreases the bioactivity of osteocalcin, an osteoblast-specific secreted molecule th

34 Osteocalcin and 17beta-estradiol mediate their effects t

35 ining the expression of bone-specific genes, osteocalcin and alkaline phosphatase as well as through

36 lls increased alkaline phosphatase activity, osteocalcin and alkaline phosphatase mRNA levels, and mi

37 ble guanylyl cyclase inhibitor ODQ increased osteocalcin and alpha-smooth muscle actin expression.

38 Osteocalcin and bone morphogenic protein (BMP)-2 express

39 decreased expression of osteoblast-specific osteocalcin and bone sialoprotein genes, alkaline phosph

40 Studies using wild-type and mutated osteocalcin and Bsp promoters revealed that Pbx1 acts th

41 Those in the lowest tertiles of total osteocalcin and carboxylated osteocalcin at baseline had

42 mined the association between 2-y changes in osteocalcin and changes in fasting glucose, insulin, HOM

43 twork and negative correlation between serum osteocalcin and Cobb angle indicate abnormal osteocyte f

44 ked surface-dependent increases in beta1 and osteocalcin and decreases in cell number and increases i

45 gy homeostasis via mechanisms independent of osteocalcin and glucose metabolism.

46 y (Tartrate-Resistant Acid Phosphatase-TRAP, Osteocalcin and human specific anti-mitochondria antibod

47 Finally, we show that the crosstalk between osteocalcin and IL-6 is conserved between rodents and hu

48 al associations between circulating forms of osteocalcin and insulin secretion and sensitivity in eld

49 Using mouse models, we found that osteocalcin and LH act in 2 parallel pathways and that o

50 However, associations between osteocalcin and measures of insulin resistance in humans

51 The vitamin D(3) -induced increase of osteocalcin and osteopontin expression was significantly

52 of vitamin D receptor (VDR)-regulated genes osteocalcin and osteopontin.

53 PCR showed a significant increase of mRNA of osteocalcin and osterix at d 14.

54 d serum markers of bone formation, including osteocalcin and procollagen type 1 N propeptide.

55 tudy expands the physiological repertoire of osteocalcin and provides the first evidence that the ske

56 lasts have low circulating undercarboxylated osteocalcin and reduced bone acquisition due to decrease

57 ers such as Runx2, alkaline phosphatase, and osteocalcin and results in decreased culture calcificati

58 Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of

59 ed material, since both the concentration of osteocalcin and the RUNX2 gene expression were considera

60 In contrast, elevated carboxylated osteocalcin and total osteocalcin were associated with l

61 Median salivary osteocalcin and tumor necrosis factor-alpha levels were

62 Changes in serum osteocalcin and ucOC are associated with an improvement

63 off system resulted in up-regulation of both osteocalcin and VEGF expression.

64 ditions: bone fragility after estrogen loss (osteocalcin) and arterial calcification linked to cardio

65 ers of osteoblastic activity, procollagen I, osteocalcin, and alkaline phosphatase.

66 Immunostaining for RUNX2 and osteocalcin, and also histochemical staining with picros

67 sialoprotein, bone morphogenetic protein-2, osteocalcin, and cementum protein (CEMP)-1 expression at

68 genes encoding Runx2, alkaline phosphatase, osteocalcin, and collagen 1alpha1, and mineralization wa

69 , and transcriptional expression of osterix, osteocalcin, and dentin matrix acidic phosphoprotein 1.

70 GCF Calprotectin, osteocalcin, and N-telopeptide of type I collagen (NTx)

71 tor kappa-B ligand (RANKL), osteoprotegerin, osteocalcin, and osteopontin as potential biomarkers of

72 Salivary concentrations of RANKL, osteocalcin, and osteopontin were higher, and osteoprote

73 ps than in the control group, whereas RANKL, osteocalcin, and osteopontin were not related with perio

74 icantly higher plasma levels of osteopontin, osteocalcin, and osteoprotegerin (204%, 148%, and 55%, r

75 nd differentiation markers (eg, osteopontin, osteocalcin, and osterix).

76 ollagen type-I N-terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transi

77 rentiated into mature osteoblasts, expressed osteocalcin, and produced COL1a2 protein, which is absen

78 ressed expression (P </=0.01) of collagen 1, osteocalcin, and Runt-related transcription factor 2 in

79 ine phosphatase, matrix metalloproteases-13, osteocalcin, and runx2, and reduced mineralization.

80 muscle segment homeobox 2, the production of osteocalcin, and the formation of calcium deposits.

81 ear receptor subfamily 4, group A, member 3; osteocalcin; and stanniocalcin 1 (STC1) but not of RUNX2

82 reacts strongly with both anti-A11 and anti-osteocalcin antibodies, detecting oligomeric, prefibrill

83 n), and bone gamma-carboxyglutamate protein (osteocalcin) are increased by 25(OH)D3 and 1alpha,25-(OH

84 Circulating osteocalcin at 12 months correlated with change in total

85 Associations between each form of osteocalcin at baseline and 3-y change in HOMA-IR were e

86 rtiles of total osteocalcin and carboxylated osteocalcin at baseline had higher baseline HOMA-IR (P =

87 The concentration of carboxylated osteocalcin at baseline was inversely associated with a

88 ding the tightly regulated late stage marker osteocalcin, become constitutively up-regulated in BRM-d

89 the transactivation of AP-1 targets such as osteocalcin (Bglap) and matrix metallopeptidase 9 (Mmp9)

90 We found that Osteocalcin (Bglap) can be used as an adult tendon-sheat

91 ineralization via transcriptional control of osteocalcin (BGLAP) gene and is the receptor for 1alpha,

92 x (Sp7), Atf4, bone sialoprotein (Ibsp), and osteocalcin (Bglap) without affecting Erk phosphorylatio

93 transcripts of alkaline phosphatase (ALPL), osteocalcin (BGLAP), osteonectin (SPARC) and osteopontin

94 odontogenic differentiation markers such as osteocalcin, bone sialoprotein, and dentin matrix protei

95 tor I without affecting parathyroid hormone, osteocalcin, bone-specific alkaline phosphatase, or tart

96 with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and fe

97 L-6), and why this deficit is correctable by osteocalcin but not by IL-6.

98 ased expressions of osterix, collagen I, and osteocalcin; but increased trabecular separation, osteoc

99 mRNA expression of osterix, collagen I, and osteocalcin by mesenchymal stem cells at 7 and 14 d of s

100 ited the transactivation activity of ATF4 on osteocalcin by preventing it to bind OSE1, the ATF4 bind

101 how that long-term treatment of WT mice with osteocalcin can significantly weaken the deleterious eff

102 vo the presence of CD163(+)/procollagen-1(+)/osteocalcin(+) cells in the fibrotic and calcified tissu

103 ation, cannot be explained by decarboxylated osteocalcin changes, suggesting existence of other osteo

104 valuated the association between circulating osteocalcin concentrations and insulin secretion and sen

105 not taking oral antidiabetic drugs, baseline osteocalcin concentrations were positively associated wi

106 After treatment, total osteocalcin concentrations were similar at 6 and 12 mo.

107 postnatal mature osteoblasts by crossing Oc (osteocalcin)-Cre mice with floxed Pkd1 (Pkd1(flox/m1Bei)

108 In contrast, in vivo excision of Dicer by Osteocalcin-Cre in mature osteoblasts generated a viable

109 Rb1 using Prx1-Cre, Collagen-1alpha1-Cre and Osteocalcin-Cre to transform undifferentiated mesenchyme

110 ese receptors in osteoblasts and osteocytes (osteocalcin-Cre).

111 Interestingly, osteocalcin-Cre;Hs2st (f/f) mice also displayed osteopor

112 rom a HFD and the involvement of insulin and osteocalcin cross-talk in glucose intolerance.

113 how here that the osteoblast-derived hormone osteocalcin crosses the blood-brain barrier, binds to ne

114 ition to these postnatal functions, maternal osteocalcin crosses the placenta during pregnancy and pr

115 Serum bone-specific alkaline phosphatase and osteocalcin decreased on paricalcitol therapy only and s

116 (increased in GG only) and insulin, leptin, osteocalcin (decreased in NGG only) at day 6 (P <=0.04),

117 Interestingly, Osteocalcin-deficient mice exhibit increased levels of l

118 of TC-PTP promotes insulin sensitivity in an osteocalcin-dependent manner.

119 abolism into myofibers during exercise in an osteocalcin-dependent manner.

120 The acidic (acidic osteocalcin-derived peptide (OSC)) and amidic (amidic os

121 in-derived peptide (OSC)) and amidic (amidic osteocalcin-derived peptide (OSN)) forms of this sequenc

122 ition rate (MAR) and expression of Runx2-II, Osteocalcin, Dmp1, and Phex.

123 oprotein (DSP), dentin matrix protein-1, and osteocalcin during a phase of reduced matrix metalloprot

124 ed in the brain, where it is involved in the osteocalcin effect on cognitive processes, and at the pe

125 nduced bone phenotype involves bone-resident osteocalcin-expressing (Ocn(+)) osteoblastic cells.

126 t metabolic homeostasis was due to increased osteocalcin expression and decreased expression of Esp,

127 eoblasts controls osteoblast development and osteocalcin expression by suppressing the Runx2 inhibito

128 the increase in mineral apposition rate and osteocalcin expression detected in vivo.

129 i-IGF1 antibody decreased Runx2 activity and osteocalcin expression in osteoblasts.

130 dulates IGF1/insulin-dependent regulation of osteocalcin expression in osteoblasts.

131 l calvarial cells and that osteoblast marker osteocalcin expression was absent.

132 At the protein level, osteocalcin expression was induced only in the DPSCs on

133 Osteoid formation and osteocalcin expression were described on the alveolar bo

134 ature, with no progression to osteopontin or osteocalcin expression.

135 ssed in proliferating osteoblasts and blocks osteocalcin expression.

136 The osteoblast-secreted molecule osteocalcin favors insulin secretion, but how this funct

137 tive marker) greater than 0.311 ng/ml, serum osteocalcin (formative marker) greater than 13.2 ng/ml,

138 staining and immunohistochemistry of GFP and osteocalcin further indicated that the grafted hBMSCs, n

139 s Runx2 activity and expression of the mouse osteocalcin gene 2 (Bglap2) in osteoblasts in vitro.

140 ing sequence in the proximal promoter of the osteocalcin gene.

141 ng osteoblast (OB)-derived undercarboxylated osteocalcin (Glu-OCN) and pancreatic beta-cell insulin;

142 to the developmental period and establishes osteocalcin/Gprc6a signaling as a major regulator of bet

143 Hence, the loss of osteocalcin/Gprc6a signaling has a profound effect on be

144 Osteocalcin has been related to insulin secretion in exp

145 The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-

146 Osteocalcin immunohistochemistry in tumors correlated we

147 s and that TRPS1 regulates the expression of osteocalcin in both cell types.

148 e-formation markers alkaline phosphatase and osteocalcin in D2J mice.

149 To determine the importance of osteocalcin in humans, we analyzed a cohort of patients

150 differentiation and the release of bioactive osteocalcin in the general circulation.

151 calcified marrow, and elevated expression of osteocalcin in the osteoblasts localized in necrotic reg

152 Bone-derived osteocalcin, in its undercarboxylated, hormonal form, re

153 collagen 1alpha1, alkaline phosphatase, and osteocalcin, in osteoblasts and PDL cells cultured on EM

154 ing expression of the phosphatase catalyzing osteocalcin inactivation.

155 This study reveals that the skeleton via osteocalcin influences cognition and contributes to the

156 Osteocalcin is an osteoblast-specific peptide that is re

157 al studies indicate that high uncarboxylated osteocalcin is associated with reduced insulin resistanc

158 The skeletal protein osteocalcin is gamma-carboxylated by vitamin K.

159 evidence that the osteoblast-derived peptide osteocalcin is one of the drivers of the metabolic deran

160 one in humans, but the endocrine function of osteocalcin is unclear.

161 s ) with different curve severity, the serum osteocalcin level was found to be significantly and nega

162 gnificant increase in OB number, serum human osteocalcin level, and trabecular bone.

163 ne-forming sites for 6 weeks increased serum osteocalcin levels and improved long bone mass and micro

164 Additionally, there is growing evidence that osteocalcin levels are a reliable marker of insulin secr

165 l smooth muscle layer, whilst both RUNX2 and Osteocalcin levels were elevated.

166 tion and mineral apposition rates as well as osteocalcin levels were increased in Lef1DeltaN transgen

167 compared with age-matched controls, whereas osteocalcin levels were normal.

168 Elevated osteocalcin levels were not detected in DEX-treated mice

169 Some of the osteocalcin-lineage-derived osteosarcomas were among the

170 three osteoblast-derived metabolic hormones (osteocalcin, lipocalin and sclerostin) and the clinical

171 e knockouts of 5 less critical VKD proteins [osteocalcin, matrix Gla protein (Mgp), growth arrest spe

172 defects and learning and memory deficits of Osteocalcin(-/-) mice is determined by the maternal geno

173 ale fertility in the mouse and suggests that osteocalcin modulates reproductive function in humans.

174 type, and delivering osteocalcin to pregnant Osteocalcin(-/-) mothers rescues these abnormalities in

175 Runx2-dependent transcriptional activity and osteocalcin mRNA expression and Bglap2 promoter activity

176 n in alkaline phosphatase (ALP) activity and osteocalcin mRNA expression was observed in p85alpha(-/-

177 ining osteopontin(+) cells were reduced, and osteocalcin mRNA in CD45(-) marrow cells was diminished.

178 in alkaline phosphatase activity, Runx-2 and osteocalcin mRNAs, and absence of mineralized matrix for

179 as Runx2, Osterix, DMP1, Bone sialoprotein, Osteocalcin, NFATc1, and Schnurri-2, which have been imp

180 Osteocalcin (OC) and matrix Gla protein (MGP) are consid

181 ineral aggregates and two adjacent proteins, osteocalcin (OC) and osteopontin (OPN).

182 R-138 with a predicted targeting site on the osteocalcin (OC) promoter resulted in a 3.7-fold reducti

183 iption factor 2, alkaline phosphatase (ALP), osteocalcin (OC), and collagen1alpha1 (COL1A1), and mine

184 ar phosphoglycoprotein (MEPE); bone markers: osteocalcin (OC), core-binding factor alpha 1 (CBFalpha1

185 vated Men1 in mature osteoblasts by crossing osteocalcin (OC)-Cre mice with floxed Men1 (Men1(f/f)) m

186 ints with active disease had lower levels of osteocalcin (OC).

187 nder the control of the osterix (Osx-Cre) or osteocalcin (Oc-Cre) promoters to generate Osx-Cre(+/-);

188 is factor [TNF]-alpha), and bone metabolism (osteocalcin [OC], carboxy-terminal collagen crosslinks [

189 c beta-cell insulin; in turn, insulin favors osteocalcin (OCN) bioactivity.

190 ntaining transcription factor that activates osteocalcin (Ocn) in osteoblasts and indian hedgehog (Ih

191 Osteocalcin (OCN) is an osteoblast-derived hormone favor

192 Osteocalcin (OCN) is an osteoblast-derived hormone that

193 Osteocalcin (OCN) is an osteoblast-derived hormone with

194 That osteocalcin (OCN) is necessary for hippocampal-dependent

195 ctor 2 (RunX2), bone sialoprotein (BSP), and osteocalcin (OCN) messenger RNA (mRNA), was evaluated us

196 rived proteins such as osteopontin (OPN) and osteocalcin (OCN) modulate osteoblast function.

197 filament protein, suppresses ATF4-dependent osteocalcin (Ocn) transcription and osteoblast different

198 n-related transcription factor 2(RUNX2), and osteocalcin (OCN) were up-regulated by FN treatment.

199 ear antigen (PCNA), bone sialoprotein (BSP), osteocalcin (OCN), and tartrate-resistant acid phosphata

200 sialoprotein (BSP), collagen type I (COL-I), osteocalcin (OCN), runt-related transcription factor 2 (

201 anxiogenic stimuli and specifically express osteocalcin (Ocn)-Cre.

202 ort that specific deletion of bone-producing osteocalcin (Ocn)-expressing cells in vivo markedly redu

203 ied by staining for the osteoblastic marker, osteocalcin (OCN).

204 ial progenitor (CD34, KDR) and osteoblastic (osteocalcin [OCN]) cell surface markers.

205 al (bone morphogenetic protein 2/4 [BMP2/4], osteocalcin [OCN], and tartrate-resistant acid phosphata

206 ng for five bone metabolism-related markers (osteocalcin [OCN], osteopontin [OPN], bone sialoprotein

207 ears to be little to no relationship between osteocalcin, or its derivative (ucOC), and glucose homeo

208 proteomic analysis of proteins bound to the osteocalcin OSE2 sequence of the mouse osteocalcin promo

209 B-cell deficient mice had similar amounts of osteocalcin(+) osteoblast bone modeling surface.

210 The expressions of alkaline phosphatase, osteocalcin, osteonectin, and osteopontin were analyzed

211 001) downregulation of alkaline phosphatase, osteocalcin, osteonectin/osteopontin, and in vitro miner

212 x2-II (Runt-related transcription factor 2), osteocalcin, osteopontin, and bone sialoprotein, were re

213 Salivary levels of RANKL, osteoprotegerin, osteocalcin, osteopontin, and serum glycosylated hemoglo

214 BMP2 was a potent inducer of osteocalcin/osteopontin (statistically significant at P

215 and osteopontin but decreased expression of osteocalcin, osteoprotegerin (mRNA and protein), and sma

216 ohistochemical analyses for the detection of osteocalcin, osteoprotegerin, receptor activator of nucl

217 of osteoblast-related genes such as Col1a1, osteocalcin, osterix and Runx2 as well as increased mine

218 ver biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025).

219 NP diet increased C-terminal telopeptide and osteocalcin (P </= 0.001 for each) despite hypercalciuri

220 on (alkaline phosphatase activity, P < 0.01; osteocalcin, P < 0.05).

221 s reveal that the osteoblast-derived hormone osteocalcin performs this endocrine function.

222 ed a significantly higher number of TRAP and Osteocalcin positive cells at 4 weeks in the cell-seeded

223 Osteocalcin positivity in XG groups was higher than in c

224 e metabolism markers (osteoprotegerin [OPG], osteocalcin, procollagen type I N-terminal propeptide, a

225 vels in the lowest tertile, higher levels of osteocalcin, procollagen type-1 N-terminal propeptide, a

226 ss and a value in the upper two tertiles for osteocalcin, procollagen type-1 N-terminal propeptide, o

227 Osteocalcin, produced by osteoblasts or released from mi

228 es osteoblast differentiation and stimulates osteocalcin production, which in turn regulates insulin

229 e osteoblastogenesis and subsequent impaired osteocalcin production.

230 mothers rescues these abnormalities in their Osteocalcin(-/-) progeny.

231 amma together with ATF4 and Runx2 stimulates osteocalcin promoter activity and endogenous mRNA expres

232 hromatin immunoprecipitation analysis of the osteocalcin promoter as a model for the behavior of the

233 paired-related homeobox gene enhancer or the osteocalcin promoter direct Cre recombinase expression t

234 o the osteocalcin OSE2 sequence of the mouse osteocalcin promoter identified TRPS1 as a regulator of

235 nstrate that the recruitment of Runx2 to the osteocalcin promoter in response to FGF2 treatment is dr

236 ere we show that TRPS1 can directly bind the osteocalcin promoter in the presence or absence of Runx2

237 t to bind OSE1, the ATF4 binding site on the osteocalcin promoter.

238 g sequence abrogates binding of TRPS1 to the osteocalcin promoter.

239 The osteoblast-derived hormone osteocalcin promotes testosterone biosynthesis in the mo

240 ndeed, chromatin immunoprecipitations of the osteocalcin proximal promoter with antibodies against Ru

241 (mean tissue/ BACKGROUND: =0.65; P=0.04) and osteocalcin (r=0.68; P=0.03) immunohistochemistry.

242 greater than 13.2 ng/ml, and beta-crosslaps/osteocalcin ratio greater than 0.024.

243 teocalcin that lead to downregulation of the osteocalcin receptor and desensitization of the beta cel

244 High serum uncarboxylated osteocalcin reflects low vitamin K status.

245 expressed in the Leydig cells of the testes, osteocalcin regulates in a CREB-dependent manner the exp

246 in or siRNA-mediated knockdown abrogates the osteocalcin response to FGF2.

247 e of carbonated apatite and the bone protein osteocalcin reveal the presence of protein-bound and fre

248 s raise the question of whether LH regulates osteocalcin's reproductive effects.

249 ake measurements on a commercially available osteocalcin sandwich ELISA kit.

250 associated with increased undercarboxylated osteocalcin secretion and altered JNK/IRS1/Akt insulin s

251 timulation of alkaline phosphatase activity, osteocalcin secretion and osteoblast mineralization.

252 n and LH act in 2 parallel pathways and that osteocalcin-stimulated testosterone synthesis is positiv

253 significantly attenuated the suppression of osteocalcin synthesis and prevented the development of i

254 also suppress osteoblast function, including osteocalcin synthesis.

255 from chronic elevations in undercarboxylated osteocalcin that lead to downregulation of the osteocalc

256 voring glucose metabolism through a hormone, osteocalcin, that becomes active once uncarboxylated.

257 n signals in osteoblasts activate a hormone, osteocalcin, that promotes glucose metabolism.

258 in circulating levels of the active form of osteocalcin, thereby decreasing insulin sensitivity in s

259 sion of both carboxylated and uncarboxylated osteocalcin through gene therapy, which additionally led

260 cription factors to suppress the activity of osteocalcin through up-regulating expression of the phos

261 as undercarboxylated forms of factor II and osteocalcin to assess tissue and functional status, resp

262 3 (Cx43), in the transcriptional response of osteocalcin to fibroblast growth factor 2 (FGF2) in MC3T

263 ned by the maternal genotype, and delivering osteocalcin to pregnant Osteocalcin(-/-) mothers rescues

264 This study extends the endocrine role of osteocalcin to the developmental period and establishes

265 al associations between circulating forms of osteocalcin (total, uncarboxylated, and carboxylated) an

266 trabecular number of femur and lumbar, serum osteocalcin, total calcium, intact parathyroid hormone,

267 enriched transcription factor that regulates osteocalcin transcription and osteoblast terminal differ

268 by small interfering RNA induced endogenous osteocalcin transcription in immature osteoblasts.

269 promoter identified TRPS1 as a regulator of osteocalcin transcription.

270 ferase reporter assays, we identify that the osteocalcin transcriptional response to FGF2 is markedly

271 ALPL expression and activity and suppressed osteocalcin transcripts in cells from male mice only.

272 amin D [25(OH)D], parathyroid hormone (PTH), osteocalcin, type I collagen C-telopeptide, hormones, an

273 Under-gamma-carboxylated osteocalcin (ucOC) increases insulin secretion and decre

274 culating concentrations of undercarboxylated osteocalcin (ucOC), in both males and females compared w

275 ne and serum percentage of undercarboxylated osteocalcin (%ucOC)] and IL-6, osteoprotegerin, and C-re

276 ation of the placebo or phylloquinone, total osteocalcin, ucOC, glucose, and insulin concentrations a

277 Total serum osteocalcin, ucOC, glucose, and insulin concentrations w

278 r, anti-IGF1 or anti-IGF1R blocked Runx2 and osteocalcin upregulation in OBs cocultured with MVNP-exp

279 Runt-related transcription factor 2 (Runx2), osteocalcin, Vega-a, and platelet endothelial cell adhes

280 alkaline phosphatase, type 1a1 collagen, and osteocalcin was also suppressed, but no change in Runx2

281 the symptomatic vs asymptomatic group, while osteocalcin was higher in asymptomatic patients with sta

282 Lower circulating uncarboxylated osteocalcin was not associated with higher HOMA-IR at ba

283 In older adults, circulating uncarboxylated osteocalcin was not associated with insulin resistance.

284 K-ligand (RANKL), osteoprotegerin (OPG), and osteocalcin was performed.

285 ted expression of type I collagen alpha1 and osteocalcin was reduced in bone of Osx::CXCR4(fl/fl) mic

286 13 amino acids present in the first helix of osteocalcin was selected based on its calcium binding ab

287 ement with the notion that IL-6 acts through osteocalcin, we demonstrate that mIL-6 promotes nutrient

288 elevated carboxylated osteocalcin and total osteocalcin were associated with lower insulin resistanc

289 rnover biomarkers N-terminal telopeptide and osteocalcin were not changed by the interventions; howev

290 near regression analysis, increases in serum osteocalcin were significantly associated with an increa

291 Tartrate-resistant acid phosphatase and osteocalcin were used to identify osteoclastic and osteo

292 nd mRNA for Runx2 and its downstream target, osteocalcin, were also increased in miR-433 decoy mouse

293 osteopontin and matrix Gla protein, but not osteocalcin, were concomitant to the level of hepatic ex

294 s, so-called 'thermostable' proteins such as osteocalcin which has been proposed as a ideal target to

295 ing reduce serum levels of undercarboxylated osteocalcin, which in turn exacerbate insulin resistance

296 In particular, the peptide hormone osteocalcin, which is made by bone and fat, appears to p

297 Recombinant osteocalcin, which is reciprocally regulated with Saa3 a

298 at secretes at least two hormones, FGF23 and osteocalcin, which regulate kidney function and glucose

299 last-related genes including osteopontin and osteocalcin, whilst the DN subset presented a transcript

300 e have increased serum levels of insulin and osteocalcin with decreased leptin levels.